Edition:
United Kingdom

Chugai Pharmaceutical Co Ltd (4519.T)

4519.T on Tokyo Stock Exchange

5,620JPY
22 Nov 2017
Change (% chg)

¥-10 (-0.18%)
Prev Close
¥5,630
Open
¥5,690
Day's High
¥5,700
Day's Low
¥5,620
Volume
814,600
Avg. Vol
844,181
52-wk High
¥5,790
52-wk Low
¥3,010

Latest Key Developments (Source: Significant Developments)

R&I affirms Chugai Pharmaceutical's rating at "AA-" and says stable outlook -R&I
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - Chugai Pharmaceutical Co Ltd <4519.T>:Says Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "AA-" -R&I.Says rating outlook stable -R&I.  Full Article

Marketing and manufacturing right transfer of 13 long-term listed products from Chugai Pharmaceutical to Taiyo Pharma
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Chugai Pharmaceutical Co Ltd <4519.T>:Says it and TAIYO HOLDINGS CO LTD <<<4626.T>>> announced today that they have entered into an agreement, under which the co and F. Hoffmann-La Roche, Ltd. will transfer the marketing authorizations, including marketing and manufacturing rights, of 13 long-term listed products manufactured and marketed in Japan by Chugai to TAIYO Pharma Co., Ltd., a wholly owned subsidiary of Taiyo Holdings.  Full Article

Chugai Pharmaceutical to retire treasury shares
Tuesday, 25 Apr 2017 

April 25(Reuters) - Chugai Pharmaceutical Co Ltd <4519.T>:Says it will retire 123,000 shares (0.02 percent of outstanding) of its common stock on April 28.  Full Article

Chugai and Galderma announce global license agreement for Nemolizumab
Thursday, 21 Jul 2016 

Chugai Pharmaceutical Co Ltd <4519.T>: Chugai will continue to be responsible for product manufacturing and supply of Nemolizumab. . Under terms of agreement, Chugai will receive an upfront, milestone and royalty payments from Galderma. . Chugai and Galderma announce global license agreement for Nemolizumab (cim331), novel biologic for skin diseases . Chugai and Galderma announce global license agreement for Nemolizumab (cim331), novel biologic for skin diseases .Chugai will grant Galderma license for development and marketing of nemolizumab worldwide, exception of Japan and Taiwan.  Full Article

Chugai Pharmaceutical says concluded a license agreement with Roche
Wednesday, 1 Jun 2016 

Chugai Pharmaceutical Co Ltd: Announced that it concluded a license agreement with roche for "sa237" .Per the terms of the agreement, chugai will receive an upfront fee, milestone and royalty payments from roche..  Full Article

Six Japanese drugmakers will team up to discover new cancer, depression treatments - Nikkei
Wednesday, 25 May 2016 

Nikkei: Astellas Pharma, Kyowa Hakko Kirin, Daiichi Sankyo, Eisai, Ono Pharmaceutical,Chugai Pharmaceutical will collaborate with 4 research institutions - Nikkei . The Six Drugmakers will work with research organizations providing cell, tissue samples to discover new pharmaceuticals - Nikkei . Around 3 billion Yen ($27.2 Million) will be put into drug-discovery efforts by fiscal 2019 - Nikkei .Group will create five teams looking into treatments for cancer, diabetic nephropathy and mental illnesses including depression - Nikkei.  Full Article

Chugai Pharmaceutical announces results of Japanese phase III study of Alecensa
Thursday, 19 May 2016 

Chugai Pharmaceutical Co Ltd : Announced results of Japanese phase III study of Alecensa in Alk fusion gene positive non-small cell lung cancer .PFS hazard ratio of Alecensa arm to Crizotinib arm was 0.34 and Alecensa demonstrated significantly prolonged PFS.  Full Article

Chugai Pharmaceutical wins Patent-Infringement lawsuit regarding OXAROL® Ointment
Friday, 25 Mar 2016 

Chugai Pharmaceutical Co Ltd:Wins a lawsuit filed by the company against companies which manufacturing and marketing their generic drugs in infringement of the process patent on "OXAROL® Ointment 25 μg/g", a Chugai's drug for treatment of keratosis including psoriasis vulgaris, on March 25.Says the grand panel judgment made by the Special Division of the Intellectual Property High Court was to reject the appeal by the generic companies, and by which, Chugai's claim was fully supported.  Full Article

Chiome Bioscience announces extension in agreement with Chugai Pharmaceutical
Thursday, 17 Dec 2015 

Chiome Bioscience Inc:Announces extension of collaborative research agreement with Chugai Pharmaceutical.Expiry date was extended to Dec. 31, 2016.  Full Article

BRIEF-R&I affirms Chugai Pharmaceutical's rating at "AA-" and says stable outlook -R&I

* Says Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "AA-" -R&I